| ALINT Stock | | | EUR 0.44 0.01 2.22% |
Director
Mr. Francis Rousseau serves as Director of Genomics of Integragen SA. He joined the Company in 2002. As Head of Laboratories, Mr. Rousseau manages the implementation of highthroughput platforms and is in charge of genotyping programs and service projects. He has worked with both small entrepreneurial biotechnological companies and pharmaceutical firms. From 2000 to 2002, Mr. Rousseau held the position of Director of Genotyping at GenOdyssee, where he set up a new genotyping facility platform. Prior to this, he managed a Lab team dedicated to the genomic programs at Aventis Pharma. As Researcher, Mr. Rousseau developed genotyping platforms and managed projects about the genetics of complex traits, such as schizophrenia, BiPolar and Parkinson diseases. He received his Doctorate Degree in Human Genetics from the Universite Paris VI Pierre and Marie Curie.
| Phone | 33 1 60 91 09 00 |
| Web | https://integragen.com |
Integragen Management Efficiency
The company has return on total asset
(ROA) of
0.0149 % which means that it generated a profit of $0.0149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Integragen's management efficiency ratios could be used to measure how well Integragen manages its routine affairs as well as how well it operates its assets and liabilities.
Integragen has accumulated 1.95
M in total debt with debt to equity ratio
(D/E) of 0.93, which is about average as compared to similar companies. Integragen has a current ratio of 1.68, which is within standard range for the sector. Debt can assist Integragen until it has trouble settling it off, either with new capital or with free cash flow. So, Integragen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Integragen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Integragen to invest in growth at high rates of return. When we think about Integragen's use of debt, we should always consider it together with cash and equity.
IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people. Integragen (ALINT) is traded on Euronext Paris in France and employs 52 people.
Management Performance
Integragen Leadership Team
Elected by the shareholders, the Integragen's board of directors comprises two types of representatives: Integragen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integragen. The board's role is to monitor Integragen's management team and ensure that shareholders' interests are well served. Integragen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integragen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA DVM, CEO Director | |
| Joerg Leenings, Head Centre | |
| JeanPol Detiffe, Chief Director | |
| Francois Liebaert, Vice President - Research & Development and Medical Affairs | |
| Emmanuel Martin, Director Sales & Marketing for the Services Business Unit | |
| Gerald Wagner, Director | |
| Brengre Gnin, Research Academics | |
| Laurence Lamotte, Director of Administration and Finance | |
| Anne Philippi, CoFounder Epidemiology | |
| Benoit Adelus, Director | |
| Bernard Courtieu, Chairman of the Board, Chief Executive Officer | |
| Philippe Boucheron, Director, representing CDC Entreprises | |
| Francis Rousseau, Director of Genomics | |
| Chantal Parpex, Director, representing CDC Innovation | |
| Louis Nisbet, Director, representing Kurma Life Sciences Partners | |
| Pierre Flamant, Adm Director | |
| Cyril Harfouche, Director | |
| Larry Yost, Chief Executive Officer - Integragen Inc | |
Integragen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integragen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to
measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to
predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.